HemaSphere
(Aug 2023)
P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL
- David Ross,
- Devendra Hiwase,
- Steven Lane,
- Kirsty Sharplin,
- Agnes Yong,
- Yeung David,
- Dale Chappell,
- Cameron Durrant,
- Timothy Hughes,
- Daniel Thomas
Affiliations
- David Ross
- 1 South Australian Health & Medical Research Institute, Adelaide, Australia
- Devendra Hiwase
- 1 South Australian Health & Medical Research Institute, Adelaide, Australia
- Steven Lane
- 2 Queensland Institute of Medical Research, Brisbane, Australia
- Kirsty Sharplin
- 1 South Australian Health & Medical Research Institute, Adelaide, Australia
- Agnes Yong
- 3 Royal Perth Hospital, Perth, Australia
- Yeung David
- 1 South Australian Health & Medical Research Institute, Adelaide, Australia
- Dale Chappell
- 4 Humanigen, Inc, Short Hills, NJ, United States
- Cameron Durrant
- 4 Humanigen, Inc, Short Hills, NJ, United States
- Timothy Hughes
- 1 South Australian Health & Medical Research Institute, Adelaide, Australia
- Daniel Thomas
- 1 South Australian Health & Medical Research Institute, Adelaide, Australia
- DOI
-
https://doi.org/10.1097/01.HS9.0000969852.23114.6d
- Journal volume & issue
-
Vol. 7
p.
e231146d
WeChat QR code